Pharmacoeconomic Evaluation on Ningmitai Capsule Combined with Levofloxacin Therapy for Chronic Prostatitis

唐富荣,余金明,唐证,张杰

DOI: https://doi.org/10.3969/j.issn.1007-6948.2016.01.008

2016-01-01

Abstract:Objective To compare the difference of the clinical efficacy therapies for chronic prostatitis be?tween levofloxacin and Ningmitai Capsule combined with levofloxacin, and evaluate their pharmacoeconomics. Methods Conducted database retrieval for meta analysis about the literatures which met criteria of domestic and imported levofloxacin to treat bacterial infections. Totally took clinical efficacy rate as index, to evaluate pharmacoeconomics with the cost-effectiveness method. Results The 6 random control trials(RCT) studies were retrieved, including 1383 patients; meta analysis showed that there was statistical significance as compared the combination of levofloxacin and Ningmitai Capsule, with single use of levofloxacin, merger OR = 1.28, 95%CI (1.21, 1.21). The economics evaluation results showed that the costs of combination treatment were higher than the single use of levofloxacin. Conclusion The combination of the drugs improves the clinical efficiency, reduces the adverse reactions and drug resistance. Although the treatment costs were increased, the drug combi?nation still has its rationality considering its indirect value.